Elizabeth R Zell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10971970/publications.pdf

Version: 2024-02-01

55 papers	12,583 citations	81900 39 h-index	149698 56 g-index
56 all docs	56 docs citations	56 times ranked	11238 citing authors

#	Article	IF	Citations
1	Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine. Pediatrics, 2017, 139, .	2.1	54
2	Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. The Lancet Global Health, 2017, 5, e359-e369.	6.3	47
3	Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine, 2017, 35, 3295-3302.	3.8	77
4	Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. Vaccine, 2017, 35, 3303-3308.	3.8	31
5	Risk Factors for Presumed Bacterial Pneumonia Among HIV-uninfected Children Hospitalized in Soweto, South Africa. Pediatric Infectious Disease Journal, 2016, 35, 1169-1174.	2.0	17
6	Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa. Clinical Infectious Diseases, 2016, 62, S188-S195.	5.8	42
7	Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infectious Diseases, The, 2015, 15, 301-309.	9.1	638
8	Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a caseâ€“control study. Thorax, 2015, 70, 1149-1155.	5.6	32
9	Risk Factors for Invasive Pneumococcal Disease Among Children Less Than 5 Years of Age in a High HIV Prevalence Setting, South Africa, 2010 to 2012. Pediatric Infectious Disease Journal, 2015, 34, 27-34.	2.0	16
10	Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants. Expert Review of Vaccines, 2015, 14, 1651-1660.	4.4	19
11	Multiple Imputation by Ordered Monotone Blocks With Application to the Anthrax Vaccine Research Program. Journal of Computational and Graphical Statistics, 2014, 23, 877-892.	1.7	23
12	Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infectious Diseases, The, 2014, 14, 1096-1104.	9.1	119
13	Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in HIV-Infected and -Uninfected Children in South Africa: A Matched Case-Control Study. Clinical Infectious Diseases, 2014, 59, 808-818.	5.8	39
14	Racial Disparities in Invasive Streptococcus pneumoniae Infections, 1998-2009. Clinical Infectious Diseases, 2014, 58, 1250-1257.	5.8	21
15	Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. New England Journal of Medicine, 2014, 371, 1889-1899.	27.0	308
16	Effectiveness of Intrapartum Antibiotic Prophylaxis for Prevention of Early-Onset Group B Streptococcal Disease. Obstetrics and Gynecology, 2013, 121, 570-577.	2.4	78
17	Prevention of Antibiotic-Nonsusceptible Streptococcus pneumoniae With Conjugate Vaccines. Journal of Infectious Diseases, 2012, 205, 401-411.	4.0	113
18	Maternal HIV Infection and Vertical Transmission of Pathogenic Bacteria. Pediatrics, 2012, 130, e581-e590.	2.1	45

#	Article	IF	Citations
19	Risk Factors for Neonatal Sepsis and Perinatal Death Among Infants Enrolled in the Prevention of Perinatal Sepsis Trial, Soweto, South Africa. Pediatric Infectious Disease Journal, 2012, 31, 821-826.	2.0	60
20	Bacterial Meningitis in the United States, 1998â€“2007. New England Journal of Medicine, 2011, 364, 2016-2025.	27.0	764
21	Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine, 2011, 29, 3398-3412.	3.8	248
22	Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2011, 30, 451-455.	2.0	55
23	Incidence and Severity of Invasive Streptococcus pneumoniae, Group A Streptococcus, and Group B Streptococcus Infections Among Pregnant and Postpartum Women. Clinical Infectious Diseases, 2011, 53, 114-123.	5.8	120
24	Risk Factors for Invasive Pneumococcal Disease in Children in the Era of Conjugate Vaccine Use. Pediatrics, 2010, 126, e9-e17.	2.1	64
25	Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998â€“2007: Implications for Prevention of Meningococcal Disease. Clinical Infectious Diseases, 2010, 50, 184-191.	5.8	390
26	Multiple Imputation in the Anthrax Vaccine Research Program. Chance, 2010, 23, 16-23.	0.2	5
27	Increasing Burden of Invasive Group B Streptococcal Disease in Nonpregnant Adults, 1990â€“2007. Clinical Infectious Diseases, 2009, 49, 85-92.	5.8	383
28	Evaluation of Universal Antenatal Screening for Group B Streptococcus. New England Journal of Medicine, 2009, 360, 2626-2636.	27.0	350
29	Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine, 2009, 27, 5061-5068.	3.8	21
30	Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet, The, 2009, 374, 1909-1916.	13.7	76
31	Nasopharyngeal Carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache Children Before the Introduction of Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2009, 28, 711-716.	2.0	40
32	Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005. JAMA - Journal of the American Medical Association, 2008, 299, 2056.	7.4	751
33	Risk Factors for Invasive Pneumococcal Disease among Navajo Adults. American Journal of Epidemiology, 2007, 166, 1080-1087.	3.4	33
34	Effect of Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization among Immunized and Unimmunized Children in a Communityâ€Randomized Trial. Journal of Infectious Diseases, 2007, 196, 1211-1220.	4.0	232
35	Invasive Methicillin-Resistant <EMPH TYPE="ITAL">Staphylococcus aureus</EMPH> Infections in the United States. JAMA - Journal of the American Medical Association, 2007, 298, 1763.	7.4	2,997
36	Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-ResistantStreptococcus pneumoniae. New England Journal of Medicine, 2006, 354, 1455-1463.	27.0	828

#	Article	IF	Citations
37	Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet, The, 2006, 368, 1495-1502.	13.7	543
38	Adults with Invasive Pneumococcal DiseaseMissed Opportunities for Vaccination. American Journal of Preventive Medicine, 2006, 31, 286-292.	3.0	28
39	Could a single dose of pneumococcal conjugate vaccine in children be effective?. Vaccine, 2006, 24, 904-913.	3.8	20
40	Preventability of Invasive Pneumococcal Disease and Assessment of Current Polysaccharide Vaccine Recommendations for Adults: United States, 2001â€“2003. Clinical Infectious Diseases, 2006, 43, 141-150.	5.8	44
41	Increased Prevalence of Pediatric Pneumococcal Serotypes in Elderly Adults. Clinical Infectious Diseases, 2005, 41, 481-487.	5.8	81
42	The Influence of Chronic Illnesses on the Incidence of Invasive Pneumococcal Disease in Adults. Journal of Infectious Diseases, 2005, 192, 377-386.	4.0	282
43	Impact of Childhood Vaccination on Racial Disparities in Invasive <EMPH TYPE="ITAL">Streptococcus pneumoniae</EMPH> Infections. JAMA - Journal of the American Medical Association, 2004, 291, 2197.	7.4	167
44	Prenatal screening for infectious diseases and opportunities for prevention. Obstetrics and Gynecology, 2003, 102, 753-760.	2.4	71
45	Effectiveness of the 23â€Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults. Journal of Infectious Diseases, 2003, 188, 81-89.	4.0	65
46	Prenatal Screening for Infectious Diseases and Opportunities for Prevention. Obstetrics and Gynecology, 2003, 102, 753-760.	2.4	45
47	Aggregated Antibiograms and Monitoring of Drug-ResistantStreptococcus pneumoniae. Emerging Infectious Diseases, 2003, 9, 1089-1095.	4.3	24
48	Association between Antimicrobial Resistance among Pneumococcal Isolates and Burden of Invasive Pneumococcal Disease in the Community. Clinical Infectious Diseases, 2002, 35, 420-427.	5.8	13
49	Epidemiology of Invasive Group AStreptococcusDisease in the United States, 1995â€“1999. Clinical Infectious Diseases, 2002, 35, 268-276.	5.8	316
50	A Population-Based Comparison of Strategies to Prevent Early-Onset Group B Streptococcal Disease in Neonates. New England Journal of Medicine, 2002, 347, 233-239.	27.0	541
51	Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine, 2002, 21, 303-311.	3.8	48
52	Sentinel Surveillance: A Reliable Way To Track Antibiotic Resistance in Communities?. Emerging Infectious Diseases, 2002, 08, 496-502.	4.3	21
53	Increasing Prevalence of Multidrug-ResistantStreptococcus pneumoniaein the United States. New England Journal of Medicine, 2000, 343, 1917-1924.	27.0	847
54	Outbreaks in Highly Vaccinated Populations: Implications for Studies of Vaccine Performance. American Journal of Epidemiology, 1994, 139, 77-90.	3.4	58

#	Article	IF	Citations
55	Mumps outbreak in a highly vaccinated population. Journal of Pediatrics, 1991, 119, 187-193.	1.8	146